PARIS--(BUSINESS WIRE)-- ExonHit Therapeutics (Paris:ALEHT)(Alternext: ALEHT) today announced the publication of Phase IIa results for EHT 0202, its lead candidate for the treatment of Alzheimer’s disease, in the journal Current Alzheimer Research. Study data demonstrate good safety and tolerability of EHT 0202 hence supporting its advancement into Phase IIb to assess clinical efficacy and confirm tolerability in a larger cohort of Alzheimer’s patients over a longer treatment duration (1).
